<DOC>
	<DOCNO>NCT00283036</DOCNO>
	<brief_summary>Study objective : To compare efficacy tolerability posology adaptation Irbesartan ambulatory Hypertensive patient</brief_summary>
	<brief_title>APROVE : Irbesartan Hypertension</brief_title>
	<detailed_description />
	<mesh_term>Hypertension</mesh_term>
	<mesh_term>Irbesartan</mesh_term>
	<criteria>Patient mild moderate hypertension define arterial diastolic pressure ( PAD ) sit position 90 mmHg 110 mmHg arterial systolic pressure ( PAS ) sit position 140 mmHg 180 mmHg . Patient diagnose 3 consultation within 2 month never treatment respond require condition hypertension treatment irbesartan . This patient must proper insufficient hygieno dietetic diet Patient none satisfy antihypertensive treatment , treatment stop least 2 week prior inclusion . Patient laboratory analysis ( urinary sediment Na K creatinine , total cholesterol ) ECG month prior inclusion . Severe Hypertension define PAS &gt; 180mmHg and/or PAD &gt; 110 mmHg . Isolated systolic Hypertension Secondary Hypertension Arterial stenosis unique kidney arterial bilateral kidney stenosis Nonsurgically sterilize woman nonmenopaused woman . Confirmed sodic depletion . Hypersensitivity Irbesartan . The information intend contain consideration relevant patient 's potential participation clinical trial .</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2008</verification_date>
</DOC>